Bavarian Nordic A/S/€BAVA
06:30
10:10
13:45
17:25
21:00
1D1W1MYTD1Y5YMAX
About Bavarian Nordic A/S
Bavarian Nordic A/S is a biotechnology company based in Denmark, primarily focused on the development, manufacture, and commercialization of vaccines for infectious diseases and cancer immunotherapies. The company's product portfolio includes vaccines for smallpox, Ebola, and other infectious diseases, with its most notable products being the smallpox and monkeypox vaccine, Jynneos (also known as Imvanex or Imvamune). Founded in 1994, Bavarian Nordic has established partnerships with several government agencies, enhancing its strategic positioning in the vaccine development sector. The company operates globally, with its headquarters located in Kvistgaard, Denmark, and manufacturing facilities in various locations supporting its international distribution efforts. Bavarian Nordic leverages proprietary vaccine platform technologies such as MVA-BN, contributing to its competitive advantage in the biotechnology industry.
Ticker
€BAVA
Sector
Primary listing
XGAT
Employees
1,738
Headquarters
Hellerup, Denmark
Website
BAVA Metrics
BasicAdvanced
€1.9B
5.98
€4.13
1.10
-
Price and volume
Market cap
€1.9B
Beta
1.1
52-week high
€33.09
52-week low
€16.50
Average daily volume
4.2K
Financial strength
Current ratio
3.837
Quick ratio
2.353
Long term debt to equity
0.693
Total debt to equity
1.019
Interest coverage (TTM)
358.69%
Profitability
EBITDA (TTM)
324.322
Gross margin (TTM)
54.33%
Net profit margin (TTM)
35.50%
Operating margin (TTM)
26.31%
Effective tax rate (TTM)
2.97%
Revenue per employee (TTM)
€529,960
Management effectiveness
Return on assets (TTM)
7.78%
Return on equity (TTM)
20.51%
Valuation
Price to earnings (TTM)
5.976
Price to revenue (TTM)
2.115
Price to book
1.09
Price to tangible book (TTM)
2.01
Price to free cash flow (TTM)
11.349
Free cash flow yield (TTM)
8.81%
Free cash flow per share (TTM)
2.173
Growth
Revenue change (TTM)
13.47%
Earnings per share change (TTM)
116.26%
3-year revenue growth (CAGR)
42.02%
10-year revenue growth (CAGR)
18.66%
3-year earnings per share growth (CAGR)
52.16%
10-year earnings per share growth (CAGR)
18.63%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bavarian Nordic A/S stock?
Bavarian Nordic A/S (BAVA) has a market cap of €1.9B as of December 18, 2025.
What is the P/E ratio for Bavarian Nordic A/S stock?
The price to earnings (P/E) ratio for Bavarian Nordic A/S (BAVA) stock is 5.98 as of December 18, 2025.
Does Bavarian Nordic A/S stock pay dividends?
No, Bavarian Nordic A/S (BAVA) stock does not pay dividends to its shareholders as of December 18, 2025.
When is the next Bavarian Nordic A/S dividend payment date?
Bavarian Nordic A/S (BAVA) stock does not pay dividends to its shareholders.
What is the beta indicator for Bavarian Nordic A/S?
Bavarian Nordic A/S (BAVA) has a beta rating of 1.1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.